BioCentury | Apr 7, 2021
Distillery Therapeutics

eIF4E identified as target in obesity, fatty liver disease

...and NAFLD activity score and improved glucose tolerance.eFFECTOR Therapeutics Inc....
BioCentury | Feb 3, 2021
Management Tracks

Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital

...area head for hemophilia A.Annette Matthies joined immunotherapy play Elicio Therapeutics as CBO. Matthies joins from eFFECTOR Therapeutics Inc....
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...NYSE:NVS; SIX:NOVN). In addition, Francis is joining Purespring seed investor Syncona Ltd. (LSE:SYNC) as a partner.eFFECTOR Therapeutics Inc....
...and as chair of its Research Triangle Park, N.C., chapter. BC Staff Purespring Therapeutics Ionis Pharmaceuticals Inc. Constellation Pharmaceuticals Inc. eFFECTOR Therapeutics Inc. MiNA...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...president. Liu was global head of research at Sanofi (Euronext:SAN; NASDAQ:SNY) in 2016-20.Premal Patel joined cancer play eFFECTOR Therapeutics Inc....
...Johnson Janssen Pharmaceuticals ​ Innovent Biologics Inc. Nautilus Biotechnology Inc. Medeor Therapeutics Inc. BeyondSpring Inc. MaxCyte Inc. Kedrion S.p.A. Jacobio Pharmaceutical Group Co. Ltd. eFFECTOR Therapeutics Inc. Epirium...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...as EVP and CSO, effective March 2. He co-founded and was SVP of research at eFFECTOR Therapeutics Inc....
BioCentury | Jan 9, 2020
Company News

Pfizer dips into translational regulation for cancer with eFFECTOR deal

...to develop small molecule inhibitors of the translation initiation complex subunit eIF4E to treat cancer. eFFECTOR Therapeutics Inc....
...mTOR (FRAP; RAFT1) - Mammalian target of rapamycin PI3K (PI3K) - Phosphoinositide 3-kinase Lauren Martz, Senior Editor eFFECTOR Therapeutics Inc. Pfizer...
BioCentury | Dec 19, 2019

Combined inhibition of EIF4A1 and glutaminase for pancreatic cancer

...in Phase II testing for breast and renal cancers, Phase II testing for solid tumors. eFFECTOR Therapeutics Inc....
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

...and James Winkler as head of degrader technologies. Webster was SVP of cancer biology at eFFECTOR Therapeutics Inc....
BioCentury | May 24, 2019
Emerging Company Profile

Anima opens new target space in translational control

...with a platform to systematically identify translational control targets and molecules. One of those companies, eFFECTOR Therapeutics Inc....
...Accent Therapeutics Inc., Lexington, Mass. Anima Biotech Inc., Bernardsville, N.J. Arrakis Therapeutics Inc., Waltham, Mass. eFFECTOR Therapeutics Inc....
BioCentury | Jan 23, 2019
Company News

Management tracks: Cabaletta, Sage, MyoKardia

...of KBP BioSciences Co. Ltd. (Jinan, China), and Vallner was VP of development operations of eFFECTOR Therapeutics Inc....
Items per page:
1 - 10 of 41
BioCentury | Apr 7, 2021
Distillery Therapeutics

eIF4E identified as target in obesity, fatty liver disease

...and NAFLD activity score and improved glucose tolerance.eFFECTOR Therapeutics Inc....
BioCentury | Feb 3, 2021
Management Tracks

Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital

...area head for hemophilia A.Annette Matthies joined immunotherapy play Elicio Therapeutics as CBO. Matthies joins from eFFECTOR Therapeutics Inc....
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...NYSE:NVS; SIX:NOVN). In addition, Francis is joining Purespring seed investor Syncona Ltd. (LSE:SYNC) as a partner.eFFECTOR Therapeutics Inc....
...and as chair of its Research Triangle Park, N.C., chapter. BC Staff Purespring Therapeutics Ionis Pharmaceuticals Inc. Constellation Pharmaceuticals Inc. eFFECTOR Therapeutics Inc. MiNA...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...president. Liu was global head of research at Sanofi (Euronext:SAN; NASDAQ:SNY) in 2016-20.Premal Patel joined cancer play eFFECTOR Therapeutics Inc....
...Johnson Janssen Pharmaceuticals ​ Innovent Biologics Inc. Nautilus Biotechnology Inc. Medeor Therapeutics Inc. BeyondSpring Inc. MaxCyte Inc. Kedrion S.p.A. Jacobio Pharmaceutical Group Co. Ltd. eFFECTOR Therapeutics Inc. Epirium...
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...as EVP and CSO, effective March 2. He co-founded and was SVP of research at eFFECTOR Therapeutics Inc....
BioCentury | Jan 9, 2020
Company News

Pfizer dips into translational regulation for cancer with eFFECTOR deal

...to develop small molecule inhibitors of the translation initiation complex subunit eIF4E to treat cancer. eFFECTOR Therapeutics Inc....
...mTOR (FRAP; RAFT1) - Mammalian target of rapamycin PI3K (PI3K) - Phosphoinositide 3-kinase Lauren Martz, Senior Editor eFFECTOR Therapeutics Inc. Pfizer...
BioCentury | Dec 19, 2019

Combined inhibition of EIF4A1 and glutaminase for pancreatic cancer

...in Phase II testing for breast and renal cancers, Phase II testing for solid tumors. eFFECTOR Therapeutics Inc....
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

...and James Winkler as head of degrader technologies. Webster was SVP of cancer biology at eFFECTOR Therapeutics Inc....
BioCentury | May 24, 2019
Emerging Company Profile

Anima opens new target space in translational control

...with a platform to systematically identify translational control targets and molecules. One of those companies, eFFECTOR Therapeutics Inc....
...Accent Therapeutics Inc., Lexington, Mass. Anima Biotech Inc., Bernardsville, N.J. Arrakis Therapeutics Inc., Waltham, Mass. eFFECTOR Therapeutics Inc....
BioCentury | Jan 23, 2019
Company News

Management tracks: Cabaletta, Sage, MyoKardia

...of KBP BioSciences Co. Ltd. (Jinan, China), and Vallner was VP of development operations of eFFECTOR Therapeutics Inc....
Items per page:
1 - 10 of 41